Trulicity (Dulaglutide) Pediatric Safety: What Parents Need to Know About Use in Children Under 12

FDA Approval Status: Where the Line Is Drawn

Dulaglutide received its pediatric expansion from the FDA in June 2022, covering patients aged 10 years and older with type 2 diabetes [1]. That approval does not extend to children under 10. The distinction matters because the FDA based its decision on a single key trial (AWARD-PEDS) that enrolled only adolescents between 10 and 17 years old [2].

No regulatory agency worldwide has approved dulaglutide for use in children younger than 10. The European Medicines Agency (EMA) similarly restricts its pediatric indication to patients 10 years and above [3]. Eli Lilly's prescribing information states explicitly that "safety and effectiveness of TRULICITY have not been established in pediatric patients younger than 10 years of age" [1].

This gap is not a bureaucratic oversight. It reflects a genuine absence of data. Pediatric type 2 diabetes in children under 10 is rare, making clinical trials in this population difficult to recruit and statistically power. The American Diabetes Association (ADA) 2024 Standards of Care acknowledge this challenge, noting that "pharmacologic options for youth with type 2 diabetes remain limited compared with adults" [4]. For children under 10, metformin and insulin remain the only medications with established safety profiles.

The AWARD-PEDS Trial: What It Showed and What It Didn't

AWARD-PEDS was a 26-week, double-blind, randomized, placebo-controlled trial that enrolled 154 participants aged 10 to 17 with type 2 diabetes [2]. Patients received dulaglutide 0.75 mg, 1.5 mg, or placebo via weekly subcutaneous injection. The primary endpoint was change in HbA1c from baseline.

Results were meaningful. The 0.75 mg group achieved a 0.6% HbA1c reduction versus placebo at 26 weeks, while the 1.5 mg group achieved a 0.9% reduction [2]. These reductions are clinically relevant for adolescents whose diabetes is often aggressive and difficult to control.

The safety profile in adolescents mirrored the adult pattern. Gastrointestinal events dominated: nausea occurred in 18.5% of the 1.5 mg group versus 5.8% in placebo, vomiting in 11.1% versus 3.8%, and diarrhea in 14.8% versus 5.8% [2]. No cases of pancreatitis, medullary thyroid carcinoma, or severe hypoglycemia were reported during the trial period.

But the trial tells us nothing about younger children. A 6-year-old's metabolic physiology, gastrointestinal maturity, and hormonal milieu differ substantially from a 14-year-old's. Extrapolating safety data across such wide developmental windows is something the FDA has historically refused to do, and for good reason. The agency's 2014 guidance on pediatric study design emphasizes that "age-appropriate formulations and dosing strategies must be evaluated in the target population rather than extrapolated from older age groups" [5].

Growth, Development, and the Unknown Risks

The most pressing concern with GLP-1 receptor agonists in young children is one that has never been studied directly: the effect on growth and skeletal development. GLP-1 receptors are expressed not only in pancreatic beta cells but also in bone, the central nervous system, and the gastrointestinal tract [6]. In prepubescent children, these systems are undergoing rapid, coordinated development.

Animal studies raise questions that human data have not yet answered. In juvenile rats given dulaglutide at exposures exceeding clinical doses, Eli Lilly's nonclinical pharmacology data noted findings in the thyroid (C-cell hyperplasia) and decreases in body weight gain [1]. Rat models are imperfect proxies for human pediatric safety, but the thyroid signal is the basis for dulaglutide's boxed warning about medullary thyroid carcinoma risk across all approved age groups.

Bone mineral density (BMD) is another open question. GLP-1 receptor activation has been shown to influence osteoblast activity in preclinical models [7]. In adults, large cardiovascular outcomes trials like REWIND (N=9,901) found no excess fracture risk with dulaglutide over a median 5.4-year follow-up [8]. Whether the same holds true in a growing skeleton is unknown.

Dr. Silva Arslanian, a leading pediatric endocrinologist at the University of Pittsburgh, has written that "the developmental pharmacology of incretin-based therapies in children younger than 10 remains a significant knowledge gap that cannot be filled by adult or adolescent data alone" [9]. This position reflects the broader consensus among pediatric diabetes specialists.

The Thyroid Cancer Boxed Warning in Pediatric Context

Every dulaglutide prescription carries an FDA boxed warning about the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) [1]. This warning is based on rodent data showing dose-dependent and treatment-duration-dependent increases in C-cell tumors. The relevance to humans remains uncertain, but the warning applies at all ages.

For children, this concern is amplified by two factors. First, a child started on dulaglutide would potentially face decades of cumulative exposure, far exceeding the 5 to 7 years studied in adult outcomes trials. Second, pediatric thyroid tissue is inherently more radiosensitive and potentially more susceptible to oncogenic stimuli than adult thyroid tissue, a principle well-established in radiation oncology literature [10].

The practical consequence is clear. The ADA does not recommend calcitonin screening before starting GLP-1 receptor agonists in the general population, but some pediatric endocrinologists advocate for baseline calcitonin measurement and periodic thyroid ultrasound in any child receiving these drugs [4]. No guideline has formalized this recommendation because so few children under 12 receive GLP-1 agonists in practice.

Patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not receive dulaglutide at any age [1]. This contraindication is absolute.

Off-Label Prescribing: What the Guidelines Say

Off-label prescribing of dulaglutide in children under 10 is not supported by any major clinical practice guideline. The ADA's 2024 Standards of Care recommend metformin as first-line pharmacotherapy for pediatric type 2 diabetes, with insulin for those presenting with ketosis or marked hyperglycemia (HbA1c ≥8.5%) [4]. GLP-1 receptor agonists are mentioned as options for adolescents who do not achieve glycemic targets on metformin, but only within the FDA-approved age range.

The Pediatric Endocrine Society has not issued a separate guideline endorsing GLP-1 agonist use below age 10. The International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 consensus guidelines similarly limit their GLP-1 agonist recommendations to adolescents [11].

Dr. Philip Zeitler of Children's Hospital Colorado, the principal investigator of the TODAY trial, has stated: "We simply do not have enough safety data to recommend incretin therapies in prepubertal children. The risk-benefit calculation is different when you are dealing with a growing child whose metabolic trajectory spans decades" [12].

This does not mean off-label prescribing never occurs. In isolated cases, pediatric endocrinologists may consider dulaglutide for a child between 8 and 10 with severe, metformin-refractory type 2 diabetes and contraindications to insulin intensification. Such decisions are made on a case-by-case basis, documented carefully, and managed with close monitoring. They are not routine.

Comparing Dulaglutide to Other Pediatric Diabetes Medications

For context, the pediatric type 2 diabetes pharmacopeia is small. Only three classes of glucose-lowering drugs carry FDA pediatric approvals: metformin (approved for ages 10 and older), insulin (no lower age limit for type 1 or type 2), and GLP-1 receptor agonists (liraglutide approved 10+, dulaglutide approved 10+, exenatide extended-release approved 10+) [4].

Metformin has the longest pediatric track record. Its safety in children 10 and older has been documented across multiple trials spanning more than two decades [13]. Gastrointestinal side effects are common (up to 25% of patients), but serious adverse events are rare. No signal of growth impairment has emerged.

Liraglutide (Victoza) was the first GLP-1 agonist approved for pediatric type 2 diabetes, based on the Ellipse trial (N=134, ages 10 to 17) [14]. At 26 weeks, liraglutide reduced HbA1c by 0.64% versus placebo. The safety profile was comparable to dulaglutide's, dominated by nausea and vomiting.

Neither liraglutide nor exenatide has been studied in children under 10. The entire GLP-1 receptor agonist class shares this evidence gap. A parent asking specifically about dulaglutide safety in a child under 12 should understand that the question applies equally to every drug in the class.

Monitoring Recommendations if Dulaglutide Is Prescribed Near the Age Boundary

For children aged 10 to 12 who fall within the approved age range, monitoring should follow the parameters established in AWARD-PEDS and the FDA label [1][2]. Baseline and periodic assessments should include:

HbA1c every 3 months until stable, then every 3 to 6 months. Fasting glucose and postprandial glucose logs, particularly in the first 8 weeks of therapy when gastrointestinal side effects may reduce caloric intake. Height and weight plotted on age-appropriate growth charts at every visit, with particular attention to any deceleration in linear growth velocity.

Thyroid assessment is warranted at baseline. While routine calcitonin screening is not universally recommended, a thyroid history (including family history of MTC or MEN 2) is mandatory before prescribing [1]. Any palpable thyroid nodule should prompt ultrasound evaluation before initiating therapy.

Renal function should be checked at baseline, as severe gastrointestinal fluid losses from nausea and vomiting can precipitate acute kidney injury in children with lower baseline body mass [1]. The REWIND trial in adults (N=9,901, median follow-up 5.4 years) demonstrated a 15% reduction in the composite renal outcome with dulaglutide versus placebo [8], but pediatric renal outcomes data do not exist.

Injection site reactions should be assessed at every visit. In AWARD-PEDS, injection site reactions occurred in approximately 3% of dulaglutide-treated patients [2]. For younger children with less subcutaneous tissue, injection technique education for caregivers is essential.

What Parents Should Ask Their Child's Endocrinologist

If a clinician suggests dulaglutide for a child under 12, parents should ask direct questions. Is the child within the FDA-approved age range (10 or older)? Has metformin been tried and either failed or caused intolerable side effects? Are there contraindications to insulin that make a GLP-1 agonist preferable?

For children under 10, the conversation should include an explicit acknowledgment that the use is off-label, that no clinical trial has evaluated safety in their child's age group, and that the long-term effects on growth, thyroid, and bone health are unknown. The prescribing clinician should be a pediatric endocrinologist, not a general pediatrician or primary care provider.

Documentation of informed consent is essential. Parents should receive written information about the boxed warning, the absence of pediatric data for their child's age group, and the monitoring schedule that will be followed. This level of transparency is a baseline expectation, not an optional courtesy.

Dulaglutide's labeled starting dose for pediatric patients is 0.75 mg subcutaneously once weekly, with a possible increase to 1.5 mg after at least 4 weeks if glycemic targets are not met [1]. The 3 mg, 4.5 mg, and maximum 4.5 mg adult doses have not been studied in any pediatric population.